Unerwünschte Arzneireaktionen an der Haut

Schlüsselwörter

unerwünschte Arzneireaktion - Exantheme - Hypersensitivitätssyndrom - Stevens-Johnson-Syndrom - toxische epidermale Nekrolyse - akute generalisierte exanthematische Pustulose

Key words

adverse drug reaction - exanthema - drug rash with eosinophilia and systemic symptoms - Stevens-Johnson syndrome - toxic epidermal necrolysis - acute generalized exanthematous pustulosis

Literatur

• 1 Allam J P, Paus T, Reichel C, Bieber T, Novak N. DRESS syndrome associated with carbamazepine and phenytoin.  Eur J Dermatol. 2004;  14 339-342
• 2 Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982.  JAMA. 1986;  256 3358-3363
• 3 Brockow K, Romano A, Blanca M. et al . General considerations for skin test procedures in the diagnosis of drug hypersensitivity.  Allergy. 2002;  57 45-51
• 4 Brooks S L. Lichenoid reaction of oral mucosa and skin to methyldopa.  J Oral Med. 1982;  37 42-44
• 5 Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab.  N Engl J Med. 2007;  357 514-515
• 6 Calista D, Morri M. Lichen planus induced by hepatitis B vaccination: a new case and review of the literature.  Int J Dermatol. 2004;  43 562-564
• 7 de Groot A C. Patch testing. 2nd ed. Elsevier Amsterdam 1994
• 8 Descamps V, Valance A, Edlinger C. et al . Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.  Arch Dermatol. 2001;  137 301-304
• 9 Duran I, Hotte S J, Hirte H. et al . Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.  Clin Cancer Res. 2007;  13 4849-4857
• 10 Gotlib V, Khaled S, Lapko I, Mar N, Saif M W. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.  Anticancer Drugs. 2006;  17 1227-1229
• 11 Gould J W, Mercurio M G, Elmets C A. Cutaneous photosensitivity diseases induced by exogenous agents.  J Am Acad Dermatol. 1995;  33 551-573
• 12 Guenther C H, Wozel G, Laske J, Aschoff R, Meurer M. Macular exanthema due to fumaric acid esters.  Ann Pharmacother. 2003;  37 234-236
• 13 Guijarro G uijarro B, Lopez S anchez AF. Lichenoid reaction caused by Clopidogrel, a new anti-platelet drug.  Med Oral. 2003;  8 33-37
• 14 Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy.  Br J Dermatol. 2005;  153 849-851
• 15 Herfs H, Schirren C G, Przybilla B, Plewig G. Das „Baboon-Syndrom”. Eine besondere Manifestation einer hämatogenen Kontaktreaktion.  Hautarzt. 1993;  44 466-469
• 16 Jamali M, El O uazzani T, Zouhair K, Lakhdar H. Carbamazepine hypersensitivity syndrome associated with cytomegalovirus reactivation.  Ann Dermatol Venereol. 2007;  134 72-73
• 17 Komericki P, Grims R, Kranke B, Aberer W. Acute generalized exanthematous pustulosis from dalteparin.  J Am Acad Dermatol. 2007;  57 718-721
• 18 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.  JAMA. 1998;  279 1200-1205
• 19 Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo R M, Delaporte E. Manifestations cutanées observées au cours d’un traitement par anti-TNF a: 11 observations.  Ann Dermatol Venereol. 2007;  134 337-342
• 20 Lim D S, Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec).  Dermatology. 2002;  205 169-171
• 21 Limentani S A, Brufsky A M, Erban J K, Jahanzeb M, Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.  J Clin Oncol. 2007;  25 1232-1238
• 22 Litt J Z. Drug eruption reference manual. 12th ed. Taylor and Francis London and New York 2006
• 23 Mittmann N, Chan B C, Knowles S, Shear N H. IVIG for the treatment of toxic epidermal necrolysis.  Skin Therapy Lett. 2007;  12 7-9
• 24 Mockenhaupt M. Schwere Arzneimittelreaktionen der Haut. Klinik und Epidemiologie.  Hautarzt. 2005;  56 24-31
• 25 Organization W H. International drug monitoring: The role of the hospital. In, Technical Report Series No 425. World Health Organization Geneva, Switzerland 1966
• 26 Pereira F A, Mudgil A V, Rosmarin D M. Toxic epidermal necrolysis.  J Am Acad Dermatol. 2007;  56 181-200
• 27 Ring J, Darsow U. Idiopathic anaphylaxis.  Curr Allergy Asthma Rep. 2002;  2 40-45
• 28 Roujeau J C, Bioulac-Sage P, Bourseau C. et al . Acute generalized exanthematous pustulosis. Analysis of 63 cases.  Arch Dermatol. 1991;  127 1333-1338
• 29 Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells.  Eur J Dermatol. 2007;  17 201-208
• 30 Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells.  Curr Opin Allergy Clin Immunol. 2002;  2 317-323
• 31 Stern R S. Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.  Arch Dermatol. 2000;  136 410-411
• 32 Van Doorn R, Kirtschig G, Scheffer E, Stoof T J, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.  Br J Dermatol. 2002;  147 598-601
• 33 Yasuda S, Mizuno N, Kawabe Y, Sakakibara S. Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine.  Photodermatol. 1988;  5 206-210
• 34 Zoller A, Schad S G, Gross G E. Erlotinib-associated skin reactions - case report and proposal for classification.  Br J Dermatol. 2006;  155 1293-1295
• 35 Zürcher K, Krebs A. Cutaneous drug reactions: an integral synopsis of today’s systemic drugs. 2nd ed. Karger Freiburg i. Br. 1998